Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim

Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Monday, Marketbeat.com reports. The firm issued a buy rating and a $12.00 price objective on the stock.

Several other brokerages have also recently weighed in on CMPX. Jefferies Financial Group lifted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Piper Sandler started coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Price Performance

CMPX stock opened at $3.11 on Monday. Compass Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $4.08. The stock has a market capitalization of $427.90 million, a price-to-earnings ratio of -8.41 and a beta of 1.17. The business’s fifty day moving average price is $2.46 and its two-hundred day moving average price is $1.90.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics during the 4th quarter worth $11,293,000. Tang Capital Management LLC grew its position in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after acquiring an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC raised its stake in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Compass Therapeutics by 512.5% in the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after purchasing an additional 227,864 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.